vs

Side-by-side financial comparison of Astria Therapeutics, Inc. (ATXS) and ReTo Eco-Solutions, Inc. (RETO). Click either name above to swap in a different company.

ReTo Eco-Solutions, Inc. is the larger business by last-quarter revenue ($1.0M vs $706.0K, roughly 1.5× Astria Therapeutics, Inc.). ReTo Eco-Solutions, Inc. runs the higher net margin — -131.6% vs -4482.0%, a 4350.4% gap on every dollar of revenue.

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for rare hematological and allergic diseases with high unmet medical needs. Its core pipeline includes drug candidates designed to address life-threatening immune-mediated conditions, serving patient populations across North America and other global markets with limited existing treatment options.

ReTo Eco-Solutions, Inc. develops and supplies eco-friendly construction materials, environmental remediation services, and solid waste treatment solutions. Its core offerings include recycled construction aggregates, soil improvement products, and ecological restoration systems, primarily serving infrastructure, real estate, and environmental conservation sectors across the Chinese market.

ATXS vs RETO — Head-to-Head

Bigger by revenue
RETO
RETO
1.5× larger
RETO
$1.0M
$706.0K
ATXS
Higher net margin
RETO
RETO
4350.4% more per $
RETO
-131.6%
-4482.0%
ATXS

Income Statement — Q3 FY2025 vs Q2 FY2025

Metric
ATXS
ATXS
RETO
RETO
Revenue
$706.0K
$1.0M
Net Profit
$-31.6M
$-1.4M
Gross Margin
17.7%
Operating Margin
-4830.6%
-133.0%
Net Margin
-4482.0%
-131.6%
Revenue YoY
36.6%
Net Profit YoY
-29.0%
-103.5%
EPS (diluted)
$-0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATXS
ATXS
RETO
RETO
Q3 25
$706.0K
Q2 25
$1.0M
Q3 24
$0
Q2 24
$768.4K
Q2 22
$2.9M
Net Profit
ATXS
ATXS
RETO
RETO
Q3 25
$-31.6M
Q2 25
$-1.4M
Q3 24
$-24.5M
Q2 24
$-678.5K
Q2 22
$-5.7M
Gross Margin
ATXS
ATXS
RETO
RETO
Q3 25
Q2 25
17.7%
Q3 24
Q2 24
43.3%
Q2 22
13.0%
Operating Margin
ATXS
ATXS
RETO
RETO
Q3 25
-4830.6%
Q2 25
-133.0%
Q3 24
Q2 24
-68.0%
Q2 22
-195.8%
Net Margin
ATXS
ATXS
RETO
RETO
Q3 25
-4482.0%
Q2 25
-131.6%
Q3 24
Q2 24
-88.3%
Q2 22
-196.4%
EPS (diluted)
ATXS
ATXS
RETO
RETO
Q3 25
$-0.55
Q2 25
Q3 24
$-0.42
Q2 24
$-0.25
Q2 22
$-0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATXS
ATXS
RETO
RETO
Cash + ST InvestmentsLiquidity on hand
$227.7M
$2.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$233.3M
$30.4M
Total Assets
$271.9M
$41.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATXS
ATXS
RETO
RETO
Q3 25
$227.7M
Q2 25
$2.5M
Q3 24
$344.3M
Q2 24
$1.6M
Q2 22
$832.4K
Stockholders' Equity
ATXS
ATXS
RETO
RETO
Q3 25
$233.3M
Q2 25
$30.4M
Q3 24
$341.7M
Q2 24
$13.3M
Q2 22
$13.5M
Total Assets
ATXS
ATXS
RETO
RETO
Q3 25
$271.9M
Q2 25
$41.4M
Q3 24
$361.6M
Q2 24
$33.7M
Q2 22
$33.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATXS
ATXS
RETO
RETO
Operating Cash FlowLast quarter
$-32.3M
$-1.6M
Free Cash FlowOCF − Capex
$-1.7M
FCF MarginFCF / Revenue
-157.4%
Capex IntensityCapex / Revenue
0.0%
5.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATXS
ATXS
RETO
RETO
Q3 25
$-32.3M
Q2 25
$-1.6M
Q3 24
$-28.0M
Q2 24
$-4.8M
Q2 22
$-9.3M
Free Cash Flow
ATXS
ATXS
RETO
RETO
Q3 25
Q2 25
$-1.7M
Q3 24
$-28.0M
Q2 24
Q2 22
FCF Margin
ATXS
ATXS
RETO
RETO
Q3 25
Q2 25
-157.4%
Q3 24
Q2 24
Q2 22
Capex Intensity
ATXS
ATXS
RETO
RETO
Q3 25
0.0%
Q2 25
5.1%
Q3 24
Q2 24
Q2 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons